nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—HRH1—atherosclerosis	0.484	1	CbGaD
Brompheniramine—CYP2B6—Simvastatin—atherosclerosis	0.0404	0.0916	CbGbCtD
Brompheniramine—CYP2C8—Simvastatin—atherosclerosis	0.0306	0.0694	CbGbCtD
Brompheniramine—CYP2C8—Lovastatin—atherosclerosis	0.03	0.0679	CbGbCtD
Brompheniramine—CYP2C8—Pravastatin—atherosclerosis	0.03	0.0679	CbGbCtD
Brompheniramine—CYP2C19—Rosuvastatin—atherosclerosis	0.0276	0.0626	CbGbCtD
Brompheniramine—CYP2C19—Simvastatin—atherosclerosis	0.0257	0.0582	CbGbCtD
Brompheniramine—CYP2C19—Lovastatin—atherosclerosis	0.0251	0.0569	CbGbCtD
Brompheniramine—CYP2D6—Niacin—atherosclerosis	0.0247	0.056	CbGbCtD
Brompheniramine—CYP2C9—Rosuvastatin—atherosclerosis	0.023	0.052	CbGbCtD
Brompheniramine—CYP2C9—Simvastatin—atherosclerosis	0.0214	0.0484	CbGbCtD
Brompheniramine—CYP2C9—Lovastatin—atherosclerosis	0.0209	0.0473	CbGbCtD
Brompheniramine—CYP2C9—Pravastatin—atherosclerosis	0.0209	0.0473	CbGbCtD
Brompheniramine—CYP2D6—Simvastatin—atherosclerosis	0.0195	0.0442	CbGbCtD
Brompheniramine—CYP2D6—Pravastatin—atherosclerosis	0.0191	0.0433	CbGbCtD
Brompheniramine—CYP2D6—Lovastatin—atherosclerosis	0.0191	0.0433	CbGbCtD
Brompheniramine—CYP3A4—Rosuvastatin—atherosclerosis	0.0134	0.0303	CbGbCtD
Brompheniramine—CYP3A4—Ezetimibe—atherosclerosis	0.0134	0.0303	CbGbCtD
Brompheniramine—CYP3A4—Simvastatin—atherosclerosis	0.0124	0.0281	CbGbCtD
Brompheniramine—CYP3A4—Pravastatin—atherosclerosis	0.0122	0.0275	CbGbCtD
Brompheniramine—CYP3A4—Lovastatin—atherosclerosis	0.0122	0.0275	CbGbCtD
Brompheniramine—Bepotastine—HRH1—atherosclerosis	0.000865	0.136	CrCbGaD
Brompheniramine—Chloropyramine—HRH1—atherosclerosis	0.000603	0.0949	CrCbGaD
Brompheniramine—Dexbrompheniramine—HRH1—atherosclerosis	0.000575	0.0906	CrCbGaD
Brompheniramine—Pheniramine—HRH1—atherosclerosis	0.000563	0.0886	CrCbGaD
Brompheniramine—Clofedanol—HRH1—atherosclerosis	0.000513	0.0807	CrCbGaD
Brompheniramine—Mepyramine—HRH1—atherosclerosis	0.000482	0.0759	CrCbGaD
Brompheniramine—Doxylamine—HRH1—atherosclerosis	0.000469	0.0738	CrCbGaD
Brompheniramine—Tripelennamine—HRH1—atherosclerosis	0.000446	0.0702	CrCbGaD
Brompheniramine—Dimetindene—HRH1—atherosclerosis	0.00041	0.0645	CrCbGaD
Brompheniramine—Bromodiphenhydramine—HRH1—atherosclerosis	0.000367	0.0577	CrCbGaD
Brompheniramine—Carbinoxamine—HRH1—atherosclerosis	0.000305	0.048	CrCbGaD
Brompheniramine—Chlorphenamine—HRH1—atherosclerosis	0.000259	0.0408	CrCbGaD
Brompheniramine—Diphenhydramine—HRH1—atherosclerosis	0.000176	0.0277	CrCbGaD
Brompheniramine—Orphenadrine—HRH1—atherosclerosis	0.000166	0.0262	CrCbGaD
Brompheniramine—Promazine—HRH1—atherosclerosis	0.000152	0.0239	CrCbGaD
Brompheniramine—CYP2C8—Metabolism—GPX1—atherosclerosis	5.71e-06	8.34e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—AGT—atherosclerosis	5.69e-06	8.32e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—APOE—atherosclerosis	5.68e-06	8.29e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—LEP—atherosclerosis	5.67e-06	8.28e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—APOE—atherosclerosis	5.67e-06	8.28e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—LEP—atherosclerosis	5.65e-06	8.26e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—APOE—atherosclerosis	5.65e-06	8.26e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—LEP—atherosclerosis	5.63e-06	8.23e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—APOE—atherosclerosis	5.63e-06	8.23e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CAV1—atherosclerosis	5.63e-06	8.22e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CAV1—atherosclerosis	5.62e-06	8.21e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—APOA1—atherosclerosis	5.61e-06	8.2e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—APOA1—atherosclerosis	5.61e-06	8.19e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CAV1—atherosclerosis	5.6e-06	8.18e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—APOA1—atherosclerosis	5.59e-06	8.16e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CAV1—atherosclerosis	5.58e-06	8.15e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—LEP—atherosclerosis	5.58e-06	8.15e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—APOE—atherosclerosis	5.58e-06	8.15e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CXCL8—atherosclerosis	5.57e-06	8.14e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—APOA1—atherosclerosis	5.57e-06	8.14e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CD36—atherosclerosis	5.56e-06	8.13e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CAV1—atherosclerosis	5.53e-06	8.07e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—APOA1—atherosclerosis	5.52e-06	8.06e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—APOB—atherosclerosis	5.47e-06	7.99e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—ESR1—atherosclerosis	5.41e-06	7.91e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—ESR1—atherosclerosis	5.4e-06	7.88e-05	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—AKT1—atherosclerosis	5.38e-06	7.86e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—ESR1—atherosclerosis	5.38e-06	7.86e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—F2—atherosclerosis	5.35e-06	7.81e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CXCL8—atherosclerosis	5.33e-06	7.79e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—F2—atherosclerosis	5.33e-06	7.79e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—ESR1—atherosclerosis	5.33e-06	7.78e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—GSTM1—atherosclerosis	5.32e-06	7.78e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—F2—atherosclerosis	5.31e-06	7.76e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—IL6—atherosclerosis	5.3e-06	7.74e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—ALB—atherosclerosis	5.28e-06	7.71e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—MTHFR—atherosclerosis	5.27e-06	7.7e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—F2—atherosclerosis	5.26e-06	7.69e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—HMOX1—atherosclerosis	5.26e-06	7.68e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—PIK3CG—atherosclerosis	5.23e-06	7.64e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—LPL—atherosclerosis	5.23e-06	7.63e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—HMOX1—atherosclerosis	5.21e-06	7.61e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.18e-06	7.57e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PPARA—atherosclerosis	5.17e-06	7.55e-05	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—AKT1—atherosclerosis	5.15e-06	7.53e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—LIPC—atherosclerosis	5.15e-06	7.52e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—PIK3CG—atherosclerosis	5.12e-06	7.48e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—APOC3—atherosclerosis	5.12e-06	7.48e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	5.12e-06	7.47e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	5.1e-06	7.45e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—GPX1—atherosclerosis	5.1e-06	7.45e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—LDLR—atherosclerosis	5.09e-06	7.43e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—PIK3CG—atherosclerosis	5.08e-06	7.43e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—IL6—atherosclerosis	5.07e-06	7.41e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—PPARG—atherosclerosis	5.05e-06	7.37e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—NOS3—atherosclerosis	5.05e-06	7.37e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—MMP9—atherosclerosis	5.04e-06	7.36e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—PIK3CG—atherosclerosis	5.04e-06	7.35e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—APOB—atherosclerosis	5.03e-06	7.35e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—AGT—atherosclerosis	5.01e-06	7.32e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—APOB—atherosclerosis	4.99e-06	7.29e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—NFKB1—atherosclerosis	4.98e-06	7.28e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CETP—atherosclerosis	4.97e-06	7.26e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CD36—atherosclerosis	4.97e-06	7.25e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—INS—atherosclerosis	4.95e-06	7.23e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—PPARG—atherosclerosis	4.95e-06	7.22e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—APOE—atherosclerosis	4.91e-06	7.17e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	4.9e-06	7.16e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—MAPK8—atherosclerosis	4.9e-06	7.16e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—GSTM1—atherosclerosis	4.9e-06	7.15e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—AKT1—atherosclerosis	4.89e-06	7.14e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	4.89e-06	7.14e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—MAPK3—atherosclerosis	4.87e-06	7.11e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CAV1—atherosclerosis	4.86e-06	7.1e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—GSTM1—atherosclerosis	4.85e-06	7.09e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—APOA1—atherosclerosis	4.85e-06	7.09e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—INS—atherosclerosis	4.85e-06	7.08e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—INS—atherosclerosis	4.84e-06	7.08e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—INS—atherosclerosis	4.83e-06	7.05e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—MMP9—atherosclerosis	4.82e-06	7.05e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—MAPK3—atherosclerosis	4.82e-06	7.04e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—INS—atherosclerosis	4.81e-06	7.03e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—LPL—atherosclerosis	4.81e-06	7.02e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—NFKB1—atherosclerosis	4.77e-06	6.97e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—INS—atherosclerosis	4.77e-06	6.96e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCL2—atherosclerosis	4.77e-06	6.96e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—LPL—atherosclerosis	4.76e-06	6.96e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.76e-06	6.95e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCL2—atherosclerosis	4.75e-06	6.94e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCL2—atherosclerosis	4.74e-06	6.92e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—MTHFR—atherosclerosis	4.71e-06	6.87e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—MAPK8—atherosclerosis	4.69e-06	6.85e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCL2—atherosclerosis	4.69e-06	6.85e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—GPX1—atherosclerosis	4.69e-06	6.85e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IGF1—atherosclerosis	4.69e-06	6.84e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—AKT1—atherosclerosis	4.68e-06	6.84e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IGF1—atherosclerosis	4.67e-06	6.82e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IGF1—atherosclerosis	4.66e-06	6.8e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—GPX1—atherosclerosis	4.65e-06	6.79e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—PTGS2—atherosclerosis	4.62e-06	6.74e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PPARA—atherosclerosis	4.62e-06	6.74e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IGF1—atherosclerosis	4.61e-06	6.73e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CD36—atherosclerosis	4.57e-06	6.67e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—ALB—atherosclerosis	4.54e-06	6.63e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CD36—atherosclerosis	4.53e-06	6.61e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—VEGFA—atherosclerosis	4.52e-06	6.61e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.49e-06	6.56e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—STAT3—atherosclerosis	4.48e-06	6.54e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—AGT—atherosclerosis	4.47e-06	6.53e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	4.45e-06	6.5e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—ALB—atherosclerosis	4.45e-06	6.49e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	4.44e-06	6.48e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PIK3CG—atherosclerosis	4.43e-06	6.47e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	4.42e-06	6.46e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—APOE—atherosclerosis	4.38e-06	6.4e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	4.38e-06	6.39e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—NOS3—atherosclerosis	4.34e-06	6.34e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CAV1—atherosclerosis	4.34e-06	6.34e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	4.33e-06	6.33e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—APOA1—atherosclerosis	4.33e-06	6.32e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.33e-06	6.32e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—MTHFR—atherosclerosis	4.29e-06	6.27e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—STAT3—atherosclerosis	4.29e-06	6.27e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	4.28e-06	6.25e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PPARG—atherosclerosis	4.27e-06	6.24e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—NOS3—atherosclerosis	4.25e-06	6.21e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NOS3—atherosclerosis	4.25e-06	6.2e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PPARA—atherosclerosis	4.25e-06	6.2e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NOS3—atherosclerosis	4.23e-06	6.18e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NOS3—atherosclerosis	4.22e-06	6.17e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PPARA—atherosclerosis	4.21e-06	6.15e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—INS—atherosclerosis	4.19e-06	6.12e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NOS3—atherosclerosis	4.18e-06	6.11e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	4.15e-06	6.07e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—AGT—atherosclerosis	4.11e-06	6.01e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	4.1e-06	5.99e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—AGT—atherosclerosis	4.08e-06	5.95e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—APOE—atherosclerosis	4.03e-06	5.88e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—ABCA1—atherosclerosis	4e-06	5.85e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—APOE—atherosclerosis	3.99e-06	5.83e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CAV1—atherosclerosis	3.99e-06	5.83e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—APOA1—atherosclerosis	3.98e-06	5.82e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	3.98e-06	5.81e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—PTGS2—atherosclerosis	3.97e-06	5.8e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CAV1—atherosclerosis	3.96e-06	5.78e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	3.95e-06	5.77e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—APOA1—atherosclerosis	3.95e-06	5.77e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—PTGS2—atherosclerosis	3.89e-06	5.68e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—ALB—atherosclerosis	3.84e-06	5.61e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PPARG—atherosclerosis	3.82e-06	5.57e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.77e-06	5.5e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	3.76e-06	5.49e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	3.74e-06	5.47e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—INS—atherosclerosis	3.74e-06	5.47e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	3.71e-06	5.42e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—NOS3—atherosclerosis	3.68e-06	5.37e-05	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.64e-06	5.32e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.64e-06	5.31e-05	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	3.63e-06	5.3e-05	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	3.62e-06	5.28e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	3.6e-06	5.26e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—IL6—atherosclerosis	3.58e-06	5.23e-05	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	3.58e-06	5.23e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	3.57e-06	5.22e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—IL6—atherosclerosis	3.56e-06	5.2e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—IL6—atherosclerosis	3.53e-06	5.15e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PPARG—atherosclerosis	3.51e-06	5.13e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PPARG—atherosclerosis	3.48e-06	5.08e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—INS—atherosclerosis	3.44e-06	5.03e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.44e-06	5.02e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—ALB—atherosclerosis	3.43e-06	5.01e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—INS—atherosclerosis	3.41e-06	4.98e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—MMP9—atherosclerosis	3.41e-06	4.98e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	3.4e-06	4.96e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—MMP9—atherosclerosis	3.39e-06	4.95e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	3.37e-06	4.93e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PTGS2—atherosclerosis	3.36e-06	4.91e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	3.36e-06	4.91e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—MMP9—atherosclerosis	3.35e-06	4.9e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	3.35e-06	4.89e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	3.32e-06	4.85e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	3.31e-06	4.84e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	3.31e-06	4.83e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	3.3e-06	4.83e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	3.29e-06	4.81e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	3.29e-06	4.81e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—APOB—atherosclerosis	3.29e-06	4.81e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	3.28e-06	4.8e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—NOS3—atherosclerosis	3.28e-06	4.79e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	3.26e-06	4.76e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	3.25e-06	4.75e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.2e-06	4.68e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—ALB—atherosclerosis	3.16e-06	4.61e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—LPL—atherosclerosis	3.14e-06	4.59e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IL6—atherosclerosis	3.13e-06	4.57e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—ALB—atherosclerosis	3.13e-06	4.57e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GPX1—atherosclerosis	3.07e-06	4.48e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	3.06e-06	4.47e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	3.05e-06	4.46e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	3.04e-06	4.44e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—STAT3—atherosclerosis	3.03e-06	4.43e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	3.02e-06	4.41e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—NOS3—atherosclerosis	3.02e-06	4.41e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	3.01e-06	4.4e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—STAT3—atherosclerosis	3.01e-06	4.4e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PTGS2—atherosclerosis	3e-06	4.38e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IL6—atherosclerosis	3e-06	4.38e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—NOS3—atherosclerosis	2.99e-06	4.37e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CD36—atherosclerosis	2.99e-06	4.36e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—STAT3—atherosclerosis	2.98e-06	4.36e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.9e-06	4.23e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—AKT1—atherosclerosis	2.89e-06	4.22e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	2.89e-06	4.22e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	2.88e-06	4.2e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	2.85e-06	4.16e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.83e-06	4.13e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.81e-06	4.1e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	2.8e-06	4.09e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	2.79e-06	4.08e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PPARA—atherosclerosis	2.78e-06	4.05e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—AKT1—atherosclerosis	2.76e-06	4.04e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	2.76e-06	4.04e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.76e-06	4.03e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PTGS2—atherosclerosis	2.74e-06	4e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—AGT—atherosclerosis	2.69e-06	3.93e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—APOE—atherosclerosis	2.63e-06	3.85e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CAV1—atherosclerosis	2.61e-06	3.81e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—APOA1—atherosclerosis	2.6e-06	3.8e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.38e-06	3.47e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—AKT1—atherosclerosis	2.32e-06	3.39e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PPARG—atherosclerosis	2.29e-06	3.35e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—INS—atherosclerosis	2.25e-06	3.29e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IL6—atherosclerosis	2.12e-06	3.09e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IL6—atherosclerosis	2.11e-06	3.08e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IL6—atherosclerosis	2.1e-06	3.07e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IL6—atherosclerosis	2.08e-06	3.04e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—ALB—atherosclerosis	2.06e-06	3.01e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—AKT1—atherosclerosis	2e-06	2.92e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—NOS3—atherosclerosis	1.97e-06	2.88e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—AKT1—atherosclerosis	1.96e-06	2.86e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.95e-06	2.85e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	1.95e-06	2.84e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—AKT1—atherosclerosis	1.94e-06	2.83e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—AKT1—atherosclerosis	1.92e-06	2.81e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.8e-06	2.64e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—AKT1—atherosclerosis	1.69e-06	2.47e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—AKT1—atherosclerosis	1.51e-06	2.2e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—AKT1—atherosclerosis	1.39e-06	2.03e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—AKT1—atherosclerosis	1.38e-06	2.01e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—AKT1—atherosclerosis	9.07e-07	1.32e-05	CbGpPWpGaD
